Literature DB >> 6333425

HLA-A2 antigen phosphorylation in vitro by cyclic AMP-dependent protein kinase. Sites of phosphorylation and segmentation in class i major histocompatibility complex gene structure.

B C Guild, J L Strominger.   

Abstract

The heavy chain of the HLA-A2 antigen is phosphorylated by cyclic AMP-dependent protein kinase at two serine residues of the intracellular region. Limited proteolysis was performed on purified [32P]HLA-A2 antigens in order to define the sites of phosphorylation. Both of the phosphorylated serine residues are located in the carboxyl terminus of the heavy chain; one is encoded by exon 5, while the other is encoded by exon 6. The phosphoserine encoded by exon 5 is part of the conserved sequence Arg-Arg-Lys-Ser-Ser. This protein sequence contains the proper arrangement of amino acids for recognition and phosphorylation by the catalytic subunit of cyclic AMP-dependent protein kinase. In the murine class I antigens (H-2), exon 5 encodes a similar sequence of basic residues followed by one intervening residue and a threonine rather than a serine residue in the last amino acid position. A composite figure is presented that compares the carboxyl-terminal sequences of human and murine class I antigens and illustrates the known sites of phosphorylation recognized by various kinases. Each site of phosphorylation in the carboxyl terminus is contained within a conserved protein sequence encoded by one of the three exons. A separation and preservation of unique sites of phosphorylation could explain why there is segmentation in the genomic arrangement of class I molecules.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6333425

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Structure, expression, and molecular mapping of a divergent member of the class I HLA gene family.

Authors:  R Srivastava; M J Chorney; S K Lawrance; J Pan; Z Smith; C L Smith; S M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

2.  Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Curr Transplant Rep       Date:  2015-05-24

3.  A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment.

Authors:  D E Geraghty; B H Koller; H T Orr
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Phosphorylation of class I histocompatibility antigens in human B lymphocytes. Regulation by phorbol esters and insulin.

Authors:  J F Peyron; M Fehlmann
Journal:  Biochem J       Date:  1988-12-15       Impact factor: 3.857

5.  Downregulation of class I major histocompatibility complex surface expression by varicella-zoster virus involves open reading frame 66 protein kinase-dependent and -independent mechanisms.

Authors:  Amie J Eisfeld; Michael B Yee; Angela Erazo; Allison Abendroth; Paul R Kinchington
Journal:  J Virol       Date:  2007-06-13       Impact factor: 5.103

6.  Variations in the cytoplasmic region account for the heterogeneity of the chicken MHC class I (B-F) molecules.

Authors:  L B Møller; J Kaufman; S Verland; J Salomonsen; D Avila; J D Lambris; K Skjødt
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

7.  HIV-1 Nef-induced down-regulation of MHC class I requires AP-1 and clathrin but not PACS-1 and is impeded by AP-2.

Authors:  Nienke B Lubben; Daniela A Sahlender; Alison M Motley; Paul J Lehner; Philippe Benaroch; Margaret S Robinson
Journal:  Mol Biol Cell       Date:  2007-06-20       Impact factor: 4.138

8.  Us3 kinase encoded by herpes simplex virus 1 mediates downregulation of cell surface major histocompatibility complex class I and evasion of CD8+ T cells.

Authors:  Takahiko Imai; Naoto Koyanagi; Ryo Ogawa; Keiko Shindo; Tadahiro Suenaga; Ayuko Sato; Jun Arii; Akihisa Kato; Hiroshi Kiyono; Hisashi Arase; Yasushi Kawaguchi
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.